799 results about "Immunopotentiation" patented technology

A medicinal composition for treating pain resulting from an inflammatory response comprises at least one pain relieving and anti-inflammatory pharmaceutical and at least one nutraceutical in a pharmaceutically acceptable base. The pharmaceutical is preferably acetaminophen or a non-steroidal anti-inflammatory drug (NSAID). The nutraceutical is preferably an immune booster, an anti-oxidant, a liver protectant, or a joint relief agent. Methods of using these compositions to treat pain caused by inflammation are also disclosed.

Methods of stimulating an immune response and treating patients responsive thereto with 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-diones, staurosporine analogs, derivatized pyridazines, chromen-4-ones, indolinones, quinazolines, nucleoside analogs, and other small molecules are disclosed. In a preferred embodiment benzopyrimidine derivatives such as ZD-6474, MLN-518, lapatinib, gefitinib or erlotinib are used.

Disclosed is a method to recover an antigen presenting cells (APCs) and immune cells rich mixture (AIM) from peripheral blood mononuclear cells (PBMC) mobilized with one or more cell adhesion inhibitors for the preparation of an AIM vaccine or an AIM adoptive immunotherapy preparation. In addition, AIM mobilization can be enhanced by priming, simultaneously or in sequence, one or more of a combination of different chemical compounds, cytokines, hormones, growth factors, etc. The interaction of chemokines and chemokine receptors enable tumor cells attachment or in close proximity to antigen presenting cells and immune cells which possess similar receptors in a micro niche environment. Severing the chemokine / chemokine receptor linkage by a cell adhesion inhibitor will release these specifically primed cell mixtures into the peripheral blood. The collection of these cells from the peripheral blood has never been described and is the basis of this invention. AIM cells can either be used alone or better still, be induced into more target specific preparations with additions, modifications and incubation, pre or post cell adhesion inhibitors mobilization, with vaccines, different target specific antigens, peptides, chemotherapeutic agents, oncolytic viral therapeutic agents, cytokines, co-stimulatory molecules, anti-regulatory T cell therapeutic agents, anti-CTLA4, anti-PD1 molecules and other methodologies of immunological enhancement known to the art. The AIM vaccine or AIM adoptive immunotherapy preparation can then be used, but not limited to, the treatment of cancer and other diseases.

Production of paclitaxel and muramic acid dipeptide conjugale as immunopotentiator and its use are disclosed. The process is carried out by combination of solid-phase chemistry and liquid-phase chemistry. It improves water solubility of paclitaxel.

The present invention provides an immunogenic composition comprising a DNA expression vector encoding both an immunopotentiating chemokine sequence as well as an immunogenic polypeptide sequence. Immunogenic polypeptide sequences are those of infectious agents or of cancerous cells. Also provided are methods of manufacturing various immunogenic compositions, and methods of using such compositions to treat cancer and infectious disease.

Influenza vaccines containing insoluble particulate adjuvants have been found to elicit an IgG response that is primarily a TH2 response (IgG1). This response can be shifted towards a TH1 response (IgG2a) by including immunopotentiators in the compositions. Thus the invention provides an immunogenic composition comprising: (i) an influenza virus antigen; (ii) an insoluble particulate adjuvant; and (iii) a immunopotentiator.

The invention provides a nibea albiflora richardson larvae and juvenile microcapsule feed which is prepared from white fish meal, euphausiid meal, squid meal, fish protein hydrolysate, feed yeast, alpha-starch, soybean lecithin, papain, fish oil, composite vitamin, composite mineral substance, binder, immunopotentiator, phagostimulant and the like. By adopting the innovated prescription and processing process, the microcapsule feed can fulfill the requirement for nutrition of larvae and juvenile growth, has the advantages of comprehensive nutrition, good palatability, high water stability, low cost and the like, can be produced in batches, is convenient for storing, transporting and feeding, is suitable for industrial breeding production, and adopts a corresponding feeding method, so that the survival rate of nibea albiflora richardson is greatly improved, the shape of the nibea albiflora richardson is increase. The nibea albiflora richardson larvae and juvenile microcapsule feed is suitable for large-scale popularization and application.

The invention discloses a water-in-oil-in-water adjuvant vaccine and a preparation method thereof. The adjuvant vaccine is composed of an internal water phase, a middle oil phase used for cladding the internal water phase, and an external water phase for cladding the middle oil phase. The external water phase comprises: a composite surfactant, a hydrophilic surfactant and mormal saline. The middle oil phase consists of: a lipophilic surfactant, a stabilizer and mineral oil. The internal water phase comprises: an immunopotentiator solution, the hydrophilic surfactant, and an inactivated antigen solution. The W / O / W (water-in-oil-in-water) type adjuvant vaccine provided in the invention can induce an immunoreaction earlier than traditional W / O (water-in-oil) type adjuvant vaccines, and can make experimental animals obtain earlier protective antibodies. The vaccine has good absorption, and causes a small inflammatory response at an inoculation site. The adjuvant vaccine disclosed in the invention has better stability than existing W / O / W type vaccines, and the antibody generation speed is fast.

Disclosed is a novel preparation of Thymosin alpha-1, which comprises Thymosin alpha-1, medicinal adjuvant and water for injection. The prepared Thymosin alpha-1 injection can be used as an immunity enhancement medicament for the treatment of chronic hepatitis B (HBV), hepatitis C (HCV), hepatocytecancer, melanocarcinoma, infectious disease, self-immune disease and malignant tumor.

The present invention provide a beta-1,3 / 1,6-glucan, a preparation method therefor, and application thereof in preparing immune enhancement and anti-tumor medicine and functional food. The preparation method comprises: drying and milling antarctic brown algae; after degreasing, water extracting, calcium chloride precipitating and anion exchanging resin purification, obtaining glucan with a beta-1,3-glucose main chain and a beta-1,6-glucose branched chain, wherein a molecular weight thereof is between 5-50 kDa. The beta-glucan prepared by the present invention has an immune enhancement activity, which is indicated by swallow of neutral red by in vitro macrophages and an NO release promoting experiment, and has a tumor growth inhibiting effect and a tumor metastasis inhibiting effect which are indicated by an in vivo animal experiment. According to the present invention, beta-1,3 / 1,6-glucan is prepared by using the antarctic brown algae; is characterized in richness and readily availability of raw material sources, simple preparation process, high product purity, strong bioactivity and easiness for industrialization; and has a prospect of being developed into immune enhancement and anti-tumor medicine.

The invention relates to a 20S-protopanaxadiol beta-cyclodextrin inclusion compound which can be used for preparing medicines and foods for resisting tumors, protecting the liver, reducing blood fat, reducing blood sugar, promoting gastric secretion, promoting appetite, improving digestion functions, enhancing immunity, resisting oxidization and resisting senescence. The invention also relates toa preparation process as well as composition of the inclusion compound.